Nplate® (romiplostim) – Expanded indication
December 14, 2018 - Amgen announced the FDA approval of Nplate (romiplostim), for the treatment of pediatric patients 1 year of age and older with immune thrombocytopenia (ITP) for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
Top